GRI Bio Past Earnings Performance
Past criteria checks 0/6
GRI Bio's earnings have been declining at an average annual rate of -63.2%, while the Biotechs industry saw earnings growing at 13% annually.
Key information
-63.2%
Earnings growth rate
-66.9%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | n/a |
| Return on equity | -5,033.6% |
| Net Margin | n/a |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses BreakdownBeta
How GRI Bio makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 0 | -13 | 8 | 3 |
| 30 Sep 23 | 0 | -13 | 9 | 2 |
| 30 Jun 23 | 0 | -12 | 8 | 1 |
| 31 Mar 23 | 0 | -5 | 3 | 0 |
| 31 Dec 22 | 0 | -3 | 2 | 0 |
| 30 Sep 22 | 0 | -1 | 1 | 0 |
| 31 Dec 21 | 0 | -2 | 1 | 0 |
Quality Earnings: GRI is currently unprofitable.
Growing Profit Margin: GRI is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if GRI's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare GRI's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: GRI is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-14%).
Return on Equity
High ROE: GRI has a negative Return on Equity (-5033.59%), as it is currently unprofitable.